Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70093 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Erika Matsuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Graves Disease, Iodine Radioisotopes, Thyrotoxicosis, Potassium Iodide. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Radioiodine therapy (RIT) is an effective treatment for Graves' disease (GD). However, some patients experience transient exacerbation of thyrotoxicosis in the mid‐to‐late‐phase period (2 weeks to several months post‐RIT), and its risk factors are poorly understood. This study aimed to investigate the clinical predictors of mid‐to‐late‐phase transient exacerbation of thyrotoxicosis following RIT.
Methods
We conducted a retrospective cohort study involving 200 Japanese patients with GD who received RIT at a single university hospital. Patients were categorized according to the clinical course as follows: no exacerbation, transient exacerbation or persistent exacerbation, likely due to residual or worsening GD. An exacerbation was defined as an increase of ≥ 1.0 pg/mL in free triiodothyronine (FT3) or ≥ 1.0 ng/dL in free thyroxine. Multivariable logistic regression, guided by the Akaike Information Criterion, was used to identify risk factors.
Results
Transient thyrotoxicosis was observed in 62 patients (31.0%). Multivariate logistic regression identified a higher 131 I dose as a significant independent risk factor (odds ratio [OR] = 1.338, 95% confidence interval [CI] = 1.048–1.710, p = 0.020). Although not statistically significant, high pre‐RIT FT3 levels and potassium iodide (KI) administration were identified as relevant predictors in the model.
Conclusions
A higher 131 I dose was an independent risk factor for mid‐to‐late‐phase transient thyrotoxicosis after RIT. Higher pre‐RIT FT3 levels and KI use may contribute to this risk. Identifying patients with these factors may be helpful for closer post‐RIT monitoring to prevent complications and avoid misdiagnosing this transient event as a treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Department of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Department of Health Care Center Yurigaoka, Mito Chuo Hospital, Mito, Ibaraki, Japan.
- Tsukuba Clinical Research and Development Organization (T-CReDO), University of Tsukuba, Tsukuba, Ibaraki, Japan.
ORCID-Profile: Kazushi Maruo
Zitieren
APA
Matsuda, E., Osaki, Y., Maruo, K., Fukazawa, H., Matsuda, T., Nakajima, R., Murayama, Y., Sugano, Y., Iwasaki, H., Sekiya, M., & Shimano, H. (2026). Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study. Clinical Endocrinology. https://doi.org/10.1111/cen.70093
Vancouver
Matsuda E, Osaki Y, Maruo K, Fukazawa H, Matsuda T, Nakajima R, et al. Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study. Clinical Endocrinology. 2026. doi:10.1111/cen.70093
BibTeX
@article{Matsuda2026,
author = {Matsuda, Erika and Osaki, Yoshinori and Maruo, Kazushi and Fukazawa, Hiroshi and Matsuda, Takaaki and Nakajima, Rikako and Murayama, Yuki and Sugano, Yoko and Iwasaki, Hitoshi and Sekiya, Motohiro and Shimano, Hitoshi},
title = {Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70093}
}
EUVIMED